Reviva Pharmaceuticals Holdings, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
Reviva Pharmaceuticals Holdings, Inc. CFO Narayan Prabhu was granted 40,925 stock options with an exercise price of $1.87, vesting over time.
OQB
Reviva Pharmaceuticals Holdings, Inc. CEO Laxminarayan Bhat received new stock option awards totaling 150,075 shares with an exercise price of $1.87.
OQB
Reviva Pharmaceuticals Holdings, Inc. director Leslie D. Funtleyder received a grant of 8,200 stock options with an exercise price of $0.5848.
OQB
Reviva Pharmaceuticals Holdings, Inc. director Richard A. Margolin was granted 8,200 stock options with an exercise price of $0.5848, vesting one year from the grant date.
OQB
Reviva Pharmaceuticals Holdings, Inc. director Purav Patel was granted 8,200 stock options with an exercise price of $0.5848, vesting one year from the grant date.
OQB
Reviva Pharmaceuticals Holdings, Inc. director Parag Saxena received 8,200 stock options with an exercise price of $0.5848, vesting in one year.
OQB
Prabhu Narayan, CFO of Reviva Pharmaceuticals, reports the acquisition of stock options for 194,250 shares.
OQB
Laxminarayan Bhat, President and CEO of Reviva Pharmaceuticals, receives stock options under the company's 2020 Equity Incentive Plan.
OQB
A Reviva Pharmaceuticals director, Purav Patel, was granted stock options for 8,200 shares at an exercise price of $2.52 per share.
OQB
Director Parag Saxena of Reviva Pharmaceuticals Holdings, Inc. was granted stock options for 8,200 shares on December 10, 2024.
OQB
Leslie D. Funtleyder, a director at Reviva Pharmaceuticals, was granted stock options for 8,200 shares on December 10, 2024.
OQB
Richard A. Margolin, a director at Reviva Pharmaceuticals, was granted 8,200 stock options on December 10, 2024, which will vest after one year.
OQB
Reviva Pharmaceuticals' CEO, Laxminarayan Bhat, and his spouse, Seema Bhat, were granted stock options as an incentive bonus in lieu of cash payment, according to a recent SEC Form 4 filing.
OQB
Chief Financial Officer of Reviva Pharmaceuticals, Prabhu Narayan, receives fully vested stock options in lieu of a cash bonus for 2023 performance.